Organigram Global vs Vanda Pharmaceuticals
Vanda Pharmaceuticals is the larger business, with $216m of revenue in fiscal 2025 against $185m for Organigram Global (1.2 times as much). Organigram Global grew faster (57.8% against 8.7%). Organigram Global kept more of each dollar of sales as profit: a net margin of -9.6% against -102.0%. Vanda Pharmaceuticals carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Organigram GlobalOGI, 2025 | Vanda PharmaceuticalsVNDA, 2025 |
|---|---|---|
| Revenue | $185m | $216m |
| Revenue growth | 57.8% | 8.7% |
| Net income | −$17.7m | −$220m |
| Operating margin | -5.9% | -70.0% |
| Net margin | -9.6% | -102.0% |
| Return on equity | -7.4% | -50.9% |
| Free cash flow | −$17.6m | −$110m |
| Cash | $60.0m | $84.9m |
| Total debt | $17,951 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 533 |
| Market value | $123m | $225m |
| Price vs our value range | — | — |
| Moat score | — | 49 (Moderate) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 6 sales |